Table 2.
Sample characteristics.
| Event rank 1 (baseline) | Event rank 2 | Event rank 3* | |
|---|---|---|---|
| n = 70 | n = 44 | n = 17 | |
| Diagnoses, No. patients | |||
| Soft tissue and other extraosseous sarcomas | 24 | 16 | 4 |
| CNS and miscellaneous intracranial and intraspinal neoplasms | 22 | 12 | 4 |
| Malignant bone tumors | 9 | 8 | 5 |
| Neuroblastoma and other peripheral nervous cell tumors | 8 | 2 | 0 |
| Hepatic tumors | 3 | 2 | 0 |
| Malignant melanomas | 2 | 2 | 2 |
| Lymphomas and reticuloendothelial neoplasms | 1 | 1 | 1 |
| Renal tumors | 1 | 1 | 1 |
| Demographics | |||
| M/F, N | 36/34 | 22/22 | 7/10 |
| Age; mean ±SD, years | 7.2 ± 5.6 | 7.5 ± 5.7 | 7.6 ± 4.7 |
| Personalized (biologically guided) approach, N | 17 | 24 | 9 |
| Treatment approaches (empirical/targeted period), N | |||
| METRO | 35/15 | 13/15 | 5/7 |
| REPUR | 20/10 | 9/11 | 6/7 |
| INHIB | 25/15 | 13/19 | 7/7 |
| SURG/RT | 57/14 | 16/11 | 6/7 |
| Events, N (%) | |||
| Progression/relapses | 46 (66%) | 16 (36%) | 5 (30%) |
| Deaths | 4 (6%) | 13 (30%) | 3 (18%) |
| Overall survival; median, years | 7.2 | ||
| Follow-up; median (min—max), months | 26 (2–141) | ||
*
Comprises 4 patients with a fourth event.